{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T07:28:07Z","timestamp":1649143687817},"reference-count":39,"publisher":"Open Access Pub","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNA"],"abstract":"<jats:p>The aim of this study was to evaluate the impact of Biofield Energy Treated\/Blessed Proprietary Test Formulation and Biofield Energy Treatment\/Blessing per se on kidney biomarkers on L-NAME and high fat diet (HFD)-induced cardiovascular disorders in Sprague Dawley rats. In this experiment, the functional kidney biomarkers such as epinephrine\/adrenaline, inducible nitric oxide synthase (iNOS), angiotensin-II, C-reactive protein (CRP), and renin were measured using ELISA assay. A test formulation was formulated including minerals (magnesium, zinc, copper, calcium, selenium, and iron), vitamins (vitamin C, vitamin B6, vitamin B12, vitamin B9, and vitamin D3), cannabidiol (CBD) isolate, Panax ginseng extract, and \u03b2-carotene. The components of the test item were divided into two; one section was defined as the untreated test formulation, while the other part and three group of animals received Mr. Mahendra Kumar Trivedi\u2019s Biofield Energy healing\/Blessing remotely for about 3 minutes. The results showed that the level of adrenaline was reduced by 31.62%, 19.58%, 34.32%, 37.07%, and 29.87% in the G5 (L-NAME + HFD + the Biofield Energy Treated test formulation), G6 (L-NAME + HFD + Biofield Energy Treatment per se to animals from day -15), G7 (L-NAME + HFD + the Biofield Energy Treated test formulation from day-15), and G8 (L-NAME + HFD + Biofield Energy Treatment per se plus the Biofield Energy Treated test formulation from day-15), and G9 (L-NAME + HFD + Biofield Energy Treatment per se animals plus the untreated test formulation) groups, respectively as compared to the disease control group (G2). Moreover, the level of iNOS was reduced by 56.76%, 49.51%, 61.79%, 57.63%, and 62.44% in the G5, G6, G7, G8, and G9 groups, respectively, as compared to the disease control group (G2). Additionally, the level of angiotensin-II was decreased by 41.09%, 34.92%, 60.65%, 53.28%, and 60.09% in the G5, G6, G7, G8, and G9 groups, respectively, as compared to the G2 group. The level of CRP was decreased by 47.21%, 38.89%, 59.81%, 55.52%, and 64.02% in the G5, G6, G7, G8, and G9 groups, respectively as compared to the G2 group. Besides, the level of renin was decreased by 20.27%, 20.13%, 12.99%, and 25.73% in the G5, G7, G8, and G9 groups, respectively as compared to the G2 group. Overall, the data suggested significance improvement of vital functional kidney biomarkers of the Biofield Energy Treated\/Blessed test formulation and Biofield Energy Treatment per se along with preventive measure on the animal with respect to various pathological conditions that might be beneficial various types of cardiovascular disorders. Therefore, the results showed the significant slowdown the inflammation-related cardiovascular disease progression and its complications\/symptoms in the preventive Biofield Energy Treatment group per se and\/or Biofield Energy Treated\/Blessed Test formulation groups (viz. G6, G7, G8, and G9).<\/jats:p>","DOI":"10.14302\/issn.2574-4488.jna-21-3847","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T10:12:35Z","timestamp":1627726355000},"page":"12-22","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Renal and Cardioprotective Potential of the Biofield Energy Treated Proprietary Test Formulation on L-NAME and High Fat Diet-Induced Cardiovascular Disorders in Sprague Dawley Rats"],"prefix":"10.14302","volume":"1","author":[{"given":"Mahendra Kumar","family":"Trivedi","sequence":"first","affiliation":[{"name":"Trivedi Global, Inc., Henderson, Nevada, USA."}]},{"given":"Alice","family":"Branton","sequence":"additional","affiliation":[{"name":"Trivedi Global, Inc., Henderson, Nevada, USA."}]},{"given":"Dahryn","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Trivedi Global, Inc., Henderson, Nevada, USA."}]},{"given":"Snehasis","family":"Jana","sequence":"additional","affiliation":[{"name":"Trivedi Science Research Laboratory Pvt. Ltd., Thane (W), Maharashtra, India."}]}],"member":"5410","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.Clifton W Callaway. (2013) Epinephrine for cardiac arrest. , Current Opinion in Cardiology 28(1), 36-42.","DOI":"10.1097\/hco.0b013e32835b0979"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.Tsutsui M, Shimokawa H, Otsuji Y, Ueta Y, Sasaguri Y et al. (2009) Nitric oxide synthases and cardiovascular diseases: Insights from genetically modified mice. , Circ J 73(6), 986-993.","DOI":"10.1253\/circj.cj-09-0208"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.Besedina A. (2016) NO-synthase activity in patients with coronary heart disease associated with hypertension of different age groups. , J Med Biochem 35(1), 43-49.","DOI":"10.1515\/jomb-2015-0008"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.Ferrario C M. (2006) Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research.J. , Renin Angiotensin Aldosterone Syst 7(1), 3-14.","DOI":"10.3317\/jraas.2006.003"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.Lemari\u00e9 C A, Schiffrin E L. (2010) The angiotensin II type 2 receptor in cardiovascular disease. , J Renin Angiotensin Aldosterone Syst 11(1), 19-31.","DOI":"10.1177\/1470320309347785"},{"key":"ref5","unstructured":"6.Cozlea D L, Farcas D M, Nagy A. (2013) The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease. , Curr Health Sci J 39(4), 225-231."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.Lagrand W K, Visser C A, Hermens W T, Niessen H W, Verheugt F W et al. (1991) C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?. , Circulation 100(1), 96-102.","DOI":"10.1161\/01.cir.100.1.96"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.Lambers Heerspink HJ, Perkovic V, D de Zeeuw. (2009) Renal and cardio-protective effects of direct renin inhibition: A systematic literature review. , J Hypertens 27(12), 2321-2331.","DOI":"10.1097\/hjh.0b013e3283310f92"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.Byrne J H, Voogt M, Turner K M, Eyles D W, McGrath J J et al. (2013) The impact of adult vitamin D deficiency on behaviour and brain function in male Sprague-Dawley rats. , PLoS One 8(8), 71593.","DOI":"10.1371\/journal.pone.0071593"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.Rayman M P. (2000) The importance of selenium to human health. , Lancet 356, 233-241.","DOI":"10.1016\/S0140-6736(00)02490-9"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.Beard J L, Connor J R. (2003) Iron status and neural functioning. , Ann Rev Nutr 23, 41-58.","DOI":"10.1146\/annurev.nutr.23.020102.075739"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.Peres F F, Lima A C, JEC Hallak, Crippa J A, Silva R H.Ab\u00edlio VC (2018) Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders? Front Pharmacol 9:. 482.","DOI":"10.3389\/fphar.2018.00482"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.Nagarkatti P, Pandey R, Rieder S A, Hegde V L, Nagarkatti M. (2009) Cannabinoids as novel anti-inflammatory drugs. , Future Med Chem 1(7), 1333-1349.","DOI":"10.4155\/fmc.09.93"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.Kang S, Min H. (2012) Ginseng, the 'Immunity Boost': The effects ofPanax ginsengon immune system. , J Ginseng Res 36(4), 354-368.","DOI":"10.5142\/jgr.2012.36.4.354"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.Maizes V, Rakel D, Niemiec C. (2009) Integrative medicine and patient-centered care. , Explore (NY) 5(5), 277-289.","DOI":"10.1016\/j.explore.2009.06.008"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.Bischof M, Del Giudice E. (2013) Communication and the emergence of collective behavior in living organisms: A quantum approach. Mol Biol Int. 987549.","DOI":"10.1155\/2013\/987549"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.Cassidy C M. (2004) What does it mean to practice an energy medicine?. , J Altern Complement Med 10(1), 79-81.","DOI":"10.1089\/107555304322848986"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.Barnes P M, Bloom B, Nahin R L. (2008) Complementary and alternative medicine use among adults and children: United States. , Natl Health Stat Report 12, 1-23.","DOI":"10.1037\/e623942009-001"},{"key":"ref18","unstructured":"19.Fan K wai. (2005) National Center for Complementary and Alternative Medicine Website. , J Med Libr Assoc 93, 410-412."},{"key":"ref19","unstructured":"20.Wisneski L, Anderson L. (2009) The Scientific Basis of Integrative Medicine. , Boca Raton, FL: 205."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.Trivedi M K, Branton A, Trivedi D, Jana S. (2021) Isotopic abundance ratio analysis of consciousness energy healing treated folic acid. , Food Nutr Current Res 4(2), 290-295.","DOI":"10.14302\/issn.2576-6694.jbbs-21-3773"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.Trivedi M K, Branton A, Trivedi D, Nayak G, Mondal S C et al. (2015) Morphological characterization, quality, yield and DNA fingerprinting of biofield energy treated alphonso mango (Mangifera indicaL.). , Journal of Food and Nutrition Sciences 3, 245-250.","DOI":"10.11648\/j.jfns.20150306.18"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.Mahendra Kumar Trivedi.Snehasis Jana (2019)In vitroassessment of the biofield treated test item on cardiac function using rat cardiomyocytes cell line (H9c2)viamultiparametric analysis. , Journal of Hypertension and Cardiology 2(4), 1-12.","DOI":"10.14302\/issn.2329-9487.jhc-19-2582"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.Trivedi M K, Branton A, Trivedi D, Jana S. (2021) Effect of consciousness energy healing treatment on the metal profile and properties of tellurium. , Eng Technol Open Acc 3(5), 555623.","DOI":"10.19080\/ETOAJ.2021.03.555623"},{"key":"ref24","unstructured":"25.Mahendra K T, Alice B, Dahryn T, Snehasis J. (2021) Consciousness energy healing treatment impacted the isotopic abundance ratio of 6-Mercaptopurine (6-MP). Nov Appro Drug Des Dev. 5(5), 555673."},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.Trivedi M K, Jana S. (2021) Anti-aging activity of biofield energy treated novel proprietary test formulation by assessment of vital biomarkers in cerebrospinal fluid (CSF) in Sprague Dawley rats. , On J Neur & Br Disord 5(2).","DOI":"10.23880\/aabsc-16000163"},{"key":"ref26","unstructured":"27.Trivedi M K, Jana S. (2021) Evaluation of biofield energy healing treatment based proprietary test formulation on gut health potential in colon cancer cell line (HT-29). , J Pharmacol Clin Res 8(4), 555743."},{"key":"ref27","unstructured":"28.Trivedi M K, Branton A, Trivedi D, Jana S. (2020) The consciousness energy healing treatment and its impact on the isotopic abundance ratio analysis of flutamide. , Drug Des Int Prop Int J 3(5)."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.C de Lucia, Femminella G D, Gambino G. (2014) Adrenal adrenoceptors in heart failure. , Front Physiol 5, 246.","DOI":"10.3389\/fphys.2014.00246"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.Tang E H, Vanhoutte P M. (2010) Endothelial dysfunction: A strategic target in the treatment of hypertension?. , Pflugers Arch 459(6), 995-1004.","DOI":"10.1007\/s00424-010-0786-4"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31.Raddino R, Caretta G, Teli M, Bonadei I, Robba D et al. (2007) Nitric oxide and cardiovascular risk factors. , Heart international 3(1), 18.","DOI":"10.4081\/hi.2007.18"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.Besedina A. (2016) NO-Synthase activity in patients with coronary heart disease associated with hypertension of different age groups. , J Med Biochem 35(1), 43-49.","DOI":"10.1515\/jomb-2015-0008"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.Ferrario C M. (2006) Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. , J Renin Angiotensin Aldosterone Syst 7(1), 3-14.","DOI":"10.3317\/jraas.2006.003"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34.Lemari\u00e9 C A, Schiffrin E L. (2010) The angiotensin II type 2 receptor in cardiovascular disease. , J Renin Angiotensin Aldosterone Syst 11(1), 19-31.","DOI":"10.1177\/1470320309347785"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.Ross T. (1993) The pathogenesis of atherosclerosis: A perspective for the 1990s. , Nature 362, 801-809.","DOI":"10.1038\/362801a0"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36.Mendall M A, Patel P, Ballam L, Strachan D, Northfield T C. (1996) C-reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study. , BMJ 312, 1061-1065.","DOI":"10.1136\/bmj.312.7038.1061"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37.Carpenter L L, Gawuga C E, Tyrka A R, Price L H. (2012) C-reactive protein, early life stress, and wellbeing in healthy adults. , Acta Psychiatr Scand 126(6), 402-410.","DOI":"10.1111\/j.1600-0447.2012.01892.x"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38.Stanton A. (2003) Potential of renin inhibition in cardiovascular disease. , J Renin Angiotensin Aldosterone Syst 4, 6-10.","DOI":"10.3317\/jraas.2003.008"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.Wood J M, Maibaum J, Rahuel J. (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. , Biochem Biophys Res Commun 308, 698-705.","DOI":"10.1016\/S0006-291X(03)01451-7"}],"container-title":["Journal of Nephrology Advances"],"original-title":[],"link":[{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T10:13:46Z","timestamp":1627726426000},"score":1,"resource":{"primary":{"URL":"https:\/\/openaccesspub.org\/jna\/article\/1650"}},"subtitle":[],"editor":[{"given":"Sasho","family":"Stoleski","sequence":"additional","affiliation":[{"name":"Institute of Occupational Health of R. Macedonia, WHO CC and Ga2len CC."}]}],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,16]]}},"URL":"https:\/\/doi.org\/10.14302\/issn.2574-4488.jna-21-3847","relation":{},"ISSN":["2574-4488"],"issn-type":[{"value":"2574-4488","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]}}}